Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL)
Condition: Lymphoma Intervention: Drug: Pembrolizumab Sponsor: Abramson Cancer Center of the University of Pennsylvania Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Lymphoma | Study | T-cell Lymphoma | University of Pennsylvania